Insider Selling: Evolus, Inc. (NASDAQ:EOLS) Insider Sells 16,582 Shares of Stock

Evolus, Inc. (NASDAQ:EOLS - Get Free Report) insider David Moatazedi sold 16,582 shares of the business's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $9.89, for a total value of $163,995.98. Following the sale, the insider now directly owns 364,927 shares of the company's stock, valued at approximately $3,609,128.03. This trade represents a 4.35% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

David Moatazedi also recently made the following trade(s):

• On Friday, June 13th, David Moatazedi sold 111,323 shares of Evolus stock. The shares were sold at an average price of $10.05, for a total value of $1,118,796.15.
• On Monday, May 12th, David Moatazedi sold 15,787 shares of Evolus stock. The stock was sold at an average price of $9.87, for a total transaction of $155,817.69.
• On Thursday, March 27th, David Moatazedi sold 6,251 shares of Evolus stock. The shares were sold at an average price of $12.40, for a total transaction of $77,512.40.

Evolus Trading Up 0.5%

Shares of EOLS stock traded up $0.05 on Thursday, reaching $9.30. The company had a trading volume of 655,952 shares, compared to its average volume of 749,252. The company has a 50-day moving average of $10.28 and a 200-day moving average of $11.71. Evolus, Inc. has a 12 month low of $8.67 and a 12 month high of $17.82. The stock has a market cap of $599.66 million, a PE ratio of -10.45 and a beta of 1.00. The company has a current ratio of 2.34, a quick ratio of 2.16 and a debt-to-equity ratio of 22.00.

Institutional Investors Weigh In On Evolus

Institutional investors have recently made changes to their positions in the company. Rhumbline Advisers lifted its position in shares of Evolus by 4.1% during the 1st quarter. Rhumbline Advisers now owns 83,436 shares of the company's stock worth $1,004,000 after buying an additional 3,287 shares during the last quarter. Jane Street Group LLC raised its position in shares of Evolus by 484.8% in the 1st quarter. Jane Street Group LLC now owns 69,947 shares of the company's stock worth $841,000 after acquiring an additional 57,987 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Evolus by 36.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,565 shares of the company's stock worth $1,883,000 after purchasing an additional 41,513 shares in the last quarter. Zimmer Partners LP increased its position in Evolus by 21.2% in the 1st quarter. Zimmer Partners LP now owns 505,000 shares of the company's stock valued at $6,075,000 after buying an additional 88,500 shares in the last quarter. Finally, Jones Financial Companies Lllp bought a new stake in Evolus in the 1st quarter valued at about $158,000. Institutional investors own 90.69% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Barclays boosted their price objective on Evolus from $22.00 to $25.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. Needham & Company LLC reiterated a "buy" rating and set a $22.00 price target on shares of Evolus in a report on Thursday, May 8th. BTIG Research began coverage on Evolus in a research note on Thursday, April 17th. They set a "buy" rating and a $21.00 price target for the company. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $27.00 price target on shares of Evolus in a research report on Thursday, April 10th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Evolus currently has an average rating of "Buy" and a consensus target price of $23.75.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.